GENE REARRANGEMENT IN LYMPHO - PROLIFERATIVE DISEASES
Ranya Mohamed Gamal;
Abstract
Lymphoid leukemias and malignant lymphomas are neoplasms characterized by proliferation of cells derived from the lymphoid tissue and its precursors.
The malignant cells in many patients who have leukemia
or lymphoma have acquired clonal chromosomal 1 abnormalities. There are two general mechanism by which chromsomal translocation results in altered gene function. The first is deregulation of gene expression which is characteristic
of the translocations in lymphoid neoplasms that involve the Ig genes in B lineage tumors and TCR genes in T lineage tumors. These rearrangement result in inappropriate expression of an oncogene with no alternation in its protein structure. The second mechanism is the expression of a novel fusion protein, resulting from the Juxtaposition of coding sequence from two genes that are normally located on different chromosomes. Such chimeric proteins are tumor specific, thus the detection of such a fusion gene or its protein product can be important in diagnosis or in the detection of residual disease or early relapse. Moreover, they may also be appropriate target for tumor specific therapies.
Lymphocyte malignancies comprise a wide spectrum of different morphologic and clinical syndromes. Therefore, the international lymphoma study group proposed a new classification termed "REAL" classification". This classification makes use of the pathologic, immunophenotypic, genetic and clinical features of a given lymphocyte tumors to delineate them into separate disease entities.
The malignant cells in many patients who have leukemia
or lymphoma have acquired clonal chromosomal 1 abnormalities. There are two general mechanism by which chromsomal translocation results in altered gene function. The first is deregulation of gene expression which is characteristic
of the translocations in lymphoid neoplasms that involve the Ig genes in B lineage tumors and TCR genes in T lineage tumors. These rearrangement result in inappropriate expression of an oncogene with no alternation in its protein structure. The second mechanism is the expression of a novel fusion protein, resulting from the Juxtaposition of coding sequence from two genes that are normally located on different chromosomes. Such chimeric proteins are tumor specific, thus the detection of such a fusion gene or its protein product can be important in diagnosis or in the detection of residual disease or early relapse. Moreover, they may also be appropriate target for tumor specific therapies.
Lymphocyte malignancies comprise a wide spectrum of different morphologic and clinical syndromes. Therefore, the international lymphoma study group proposed a new classification termed "REAL" classification". This classification makes use of the pathologic, immunophenotypic, genetic and clinical features of a given lymphocyte tumors to delineate them into separate disease entities.
Other data
| Title | GENE REARRANGEMENT IN LYMPHO - PROLIFERATIVE DISEASES | Other Titles | اعادة الترتيب الجينى فى امراض التكاثر اللمفى | Authors | Ranya Mohamed Gamal | Issue Date | 2001 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.